Profluent

Executive Summary

Profluent is a Berkeley-based biotechnology company founded in 2022 that leverages advanced artificial intelligence and machine learning to design novel, functional proteins. The company's core mission is to move beyond discovering biology in nature to actively authoring new biological solutions, with applications spanning therapeutics, agriculture, and industrial enzymes. Profluent's flagship demonstration is OpenCRISPR, the world's first AI-designed gene editor, which showcases its capability to create functional proteins not found in nature. The company operates at the intersection of AI and synthetic biology, aiming to revolutionize protein engineering by generating diverse, high-performance proteins for various industries. Despite being in early stages, Profluent's innovative approach and focus on AI-driven design position it as a potential disruptor in the biotech landscape, with OpenCRISPR representing a significant leap in gene editing technology.

Upcoming Catalysts (preview)

• Q4 2026Publication of preclinical data for OpenCRISPR or other AI-designed proteins70% success
• Q2 2027Announcement of strategic partnership with a pharmaceutical or agricultural company50% success
• Q3 2026Closing of Series A financing round60% success